- Home
- MBLY vs TSHA Comparison
MBLY vs TSHA Comparison
Compare MBLY & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBLY | TSHA |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | Israel | United States |
| Employees | 4200 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MBLY | TSHA |
|---|---|---|
| Price | $8.23 | $5.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 8 |
| Target Price | ★ $14.13 | $11.63 |
| AVG Volume (30 Days) | ★ 8.7M | 3.2M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.43 | 5.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,894,000,000.00 | $9,773,000.00 |
| Revenue This Year | $4.91 | N/A |
| Revenue Next Year | $13.94 | $1,152.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 14.51 | ★ 17.28 |
| 52 Week Low | $6.47 | $2.54 |
| 52 Week High | $15.81 | $7.30 |
Technical Indicators
Market Signals| Indicator | MBLY | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 41.27 |
| Support Level | $7.66 | $5.28 |
| Resistance Level | $10.01 | $6.01 |
| Average True Range (ATR) | 0.59 | 0.46 |
| MACD | -0.15 | -0.07 |
| Stochastic Oscillator | 35.04 | 15.03 |
Price Performance
Historical ComparisonAbout MBLY Mobileye Global Inc.
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Moovit. The solutions provided by the company are: Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.